Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers

Journal of Nuclear Medicine

Volumn 41, Issue 4, 2000, Pages 584-589

  Mozley, P David ^a   Schneider, Jay S ^a   Acton, Paul D ^a   Plössl, Karl ^a   Stern, Matthew B ^a   Siderowf, Andrew ^a   Leopold, Norman A ^a   Li, Pei Yong ^a   Alavi, Abass ^a   Kung, Hank F ^a  

^a HUP ^*

Author keywords

Movement disorders; Normal; Parkinson's disease; SPECT

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; CARRIER PROTEIN; DIAGNOSTIC AGENT; DOPAMINE; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT 1; TECHNETIUM TC 99M TRODAT-1; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN CIRCULATION; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DISCRIMINANT ANALYSIS; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; BRAIN; CASE CONTROL STUDY; IMAGE PROCESSING; METABOLISM; SCINTISCANNING;

ADULT; AGED; BRAIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TROPANES;

EID: 0033625124     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharm Sci. 1993;14:43-49.
2. Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: a crucial component regulating dopamine transmission. Movement Disord. 1997;12:629-633.
3. Meegalla S, Plossl K, Kung MP, et al. Tc-99m-labeled tropanes as dopamine transporter imaging agents. Bioconjugate Chem. 1996;7:421-429.
4. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med. 1996;23:1527-1530.
5. Meegalla SK, Plossl K, Kung MP, et al. Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J Med Chem. 1997;40:9-17.
6. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372-380.
7. 99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 1998;41:428-436.
8. Mozley PD, Stubbs JB, Plossl K, et al. The biodistribution and dosimetry of a [Tc-99m] labeled tropane for imaging dopamine transporters. J Nucl Med. 1998;39:2069-2076.
9. Steigman J, Eckelman, WC. The Chemistry of Technetium in Medicine. Washington, DC: National Academy Press; 1992.
10. Mozley PD, Acton PD, Barraclough ED, et al. Effects of age on the cerebral distribution of [Tc-99m]TRODAT-1 in healthy humans. J Nucl Med. 1999;40:1812-1817.
11. 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
12. Innis RB, Seibyl JP, Scanley BE, et al. Single-photon emission computed tomography imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
13. Kim HJ, Im JH, Yang SO, et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med. 1997;38:1703-1711.
14. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology. 1997;48:1578-1583.
15. Tatsch K, Schwarz J, Mozley PD, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [I-123] IPT single-photon emission tomography. Ear J Nucl Med 1997;34:415-421.
16. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med. 1998;339:1044-1053.
17. Lang AE, Lozano AM. Parkinson's disease: second of two parts. N Engl J Med. 1998;339:1130-1143.
18. Johnston BT, Li Q, Castell JA, Castell DO. Swallowing and esophageal function in Parkinson's disease. Am J Gastroenterol. 1995;90:1741-1746.
19. 99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med. 1998;25:31-39.
20. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638-643.
21. Borasio GD, Linke R, Schwarz J, et al. Dopaminergic deficit in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1998;65:263-265.
22. Hoh CK, Dahlbom M, Harris G, et al. Automated iterative three-dimensional registration of positron emission tomography images. J Nucl Med. 1993;34:2009-2018.
23. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RSJ. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab. 1990;10:458-466.
24. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric mapping in functional imaging: a general linear approach. Hum Brain Mapping. 1995;2:189-210.
25. Acton PD, Friston KF. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25:663-667.
26. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapping. 1994;1:214-220.
27. Worsley KJ. Local maxima and the expected Euler characteristic of excursion sets of chi-2, F and t fields. Adv Appl Prob. 1994;26:13-42.
28. McLachlan GJ. Discriminant Analysis and Statistical Pattern Recognition. New York, NY: John Wiley & Sons: 1992:255-282.
29. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurolology. 1996;46:231-237.
30. Tissingh G, Booij J, Hermans P, et al. Iodine-123-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane SPECT in healthy controls and early-stage, drug naive Parkinson's disease. J Nucl Med. 1998;39:1143-1148.